Tsubota Laboratory Inc
TSE:4890
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
310
445
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
T
|
Tsubota Laboratory Inc
TSE:4890
|
8.2B JPY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
972.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.3B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
93.8B EUR |
Loading...
|
Market Distribution
| Min | -125 500% |
| 30th Percentile | 4.2% |
| Median | 7% |
| 70th Percentile | 10.6% |
| Max | 9 743.7% |
Other Profitability Ratios
Tsubota Laboratory Inc
Glance View
Tsubota Laboratory Inc is a JP-based company operating in Pharmaceuticals industry. The company is headquartered in Shinjuku, Tokyo-To and currently employs 9 full-time employees. The company went IPO on 2022-06-23. Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The firm operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The firm is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Tsubota Laboratory Inc is -19%, which is above its 3-year median of -53.8%.
Over the last 3 years, Tsubota Laboratory Inc’s Operating Margin has decreased from 21.8% to -19%. During this period, it reached a low of -446.6% on Dec 31, 2023 and a high of 30.8% on Dec 31, 2024.